AI-Powered Cervical Cancer Screening Comes to Alentejo Hospital

The Évora Hospital, under the management of the Alentejo Central Local Health Unit (ULSAC), has become the only public medical facility in Portugal currently deploying artificial intelligence for cervical cancer screening, a development that distinguishes the Alentejo region as a proving ground for diagnostic innovation within the national health system.

Why This Matters

• Single active deployment: Évora is currently Portugal's only public hospital operating AI-assisted cervical cytology screening at clinical scale.

• Regional reach with rural advantage: The Alentejo covers roughly 700,000 residents across one of Europe's least densely populated regions—a geography where specialist pathologists are scarce and diagnostic delays are common.

• Precision over volume: The system achieves detection accuracy above 95% for high-grade precancerous lesions, compared to 70–85% manual screening, narrowing the window between abnormality and clinical intervention.

• Alignment with WHO targets: Combined HPV vaccination and AI screening position the region to meet the World Health Organization's 2030 elimination roadmap for cervical malignancy.

Practical Impact for Alentejo Residents

If you seek gynecological care through ULSAC facilities or reside in the Alentejo, three tangible operational shifts become effective:

Accelerated reporting: Digital image processing and algorithmic prioritization compress the diagnostic timeline. What once took 4–6 weeks now potentially resolves within days, allowing earlier notification of abnormal findings and faster access to follow-up colposcopy or biopsy procedures.

Reduced variability: Manual microscopy introduces subjective interpretation—two pathologists examining the same slide may reach divergent conclusions. Algorithm-driven scoring minimizes this inconsistency, ensuring that cervical abnormalities meet uniform detection thresholds regardless of which technician reviewed the case.

Retrievable records: Digital archiving enables you to obtain past results, request second opinions, or transfer your screening history to another provider without hunting for physical slides or waiting for records departments to locate paper files. This is particularly valuable for women moving between regions or requiring private specialist consultation.

How to access this screening: Screening is automatic for eligible women within ULSAC's screening program—no special request is needed. Your existing appointment schedule remains unchanged. If you receive HPV-positive results, your sample will be processed through the AI system as part of routine cytology analysis. There are no additional eligibility criteria or patient costs associated with this advancement.

The Machine Behind the Microscope

The technology, branded Genius Digital Imager and manufactured by Hologic, performs a discrete but consequential task: it digitizes traditional Pap smear slides and applies trained algorithms to scan cells at high magnification, flagging clusters for human expert review.

A patient's cervical sample arrives as a glass slide. ULSAC first applies genotyping, a molecular test that detects human papillomavirus DNA. If the test returns positive for high-risk strains—chiefly types 16 and 18, responsible for roughly 70% of cervical malignancies—the sample progresses to analysis. This is where the Genius Digital Imager intervenes. It digitizes the slide, then deploys pattern-recognition algorithms to identify cellular markers of viral infection. The system does not diagnose; it highlights and ranks suspicious areas for a pathologist or cytotechnician to confirm.

Carlos Quintana, director of ULSAC's Pathology Service, frames the innovation as augmentation rather than replacement. "We are not displacing clinical expertise," he states. "We are extending the speed and consistency of expert judgment, enabling our team to process regional screening volume without sacrificing diagnostic rigor." Every image, annotation, and decision log remains stored digitally, creating an auditable trail that mitigates the risk of misfiled slides or transcription errors—a persistent vulnerability in manual paper-based systems.

Performance and Context

The AI system achieves detection accuracy above 95% for high-grade precancerous lesions—significantly outperforming conventional manual screening, which typically ranges between 70% and 85% depending on technician experience and laboratory volume. Published research confirms that algorithm-assisted screening identifies more cancers while reducing human workload, a combination that translates directly to better outcomes for regional populations.

What Remains Uncertain

No algorithm is infallible. The principal risk is false negatives—cancerous or precancerous cells that the system misses and thus never presents for human review. This is why ULSAC mandates that trained cytotechnicians review every flagged case; the AI performs triage and highlighting, not final diagnosis. An undetected high-grade lesion could delay treatment and worsen prognosis, offsetting the system's efficiency gains.

Data governance presents a secondary concern. Although the Genius Digital Imager operates on-premises without transmitting slides to external servers, the European Union AI Act requires transparency logs and algorithmic bias audits. ULSAC has not disclosed whether Hologic's trained model incorporates diverse European populations or relies predominantly on other datasets. If performance variances emerge, independent auditing will be essential.

The Roadmap Beyond Évora

Portugal's National Health Service (SNS) has signaled interest in integrating AI across pathology and radiology. Évora's implementation demonstrates that localized deployment is feasible, potentially catalyzing adoption across other regional health centers.

The new Central Hospital of Alentejo—also located in Évora—approaches completion in late 2026 or early 2027. That facility will inherit the existing Genius Digital Imager infrastructure and is expected to expand AI modules for guidance during colposcopy and automated biopsy site identification. If successful, this cascade effect could position newer hospitals as early adopters, creating momentum for procurement in Lisbon, Porto, and Coimbra academic medical centers by 2027 or 2028.

Portugal is also positioned to contribute to the European Union's Cancer Image Europe (EUCAIM) initiative, which aggregates anonymized oncology imaging from member states to refine algorithms. Hospitals that digitize workflows early can feed data into this collective intelligence and access emerging insights without waiting for isolated local studies.

A Broader Strategic Shift

Cervical cancer stands apart among malignancies: it has a defined viral cause, a well-characterized progression from dysplasia to invasion, and a vaccine that prevents infection. The World Health Organization has declared a 2030 elimination target: 90% HPV vaccination coverage, 70% screening coverage by age 35, and 90% treatment access for identified lesions.

Portugal's national HPV immunization program, initiated in 2008 for girls aged 13, achieved 85% uptake by 2020 but has not expanded to boys—a gap that perpetuates transmission and keeps the virus circulating in the population. Pairing comprehensive vaccination with enhanced AI-augmented screening could position Portugal ahead of the WHO roadmap, particularly in rural and underserved zones where specialist cytopathologists are thin on the ground.

For now, the Alentejo functions as Portugal's clinical laboratory. If outcomes prove successful, the SNS may greenlight procurement for additional health centers within 18–24 months. That trajectory would make Portugal one of southern Europe's first countries to standardize AI cytology screening in its public system, a milestone worth noting in a health service still contending with pandemic backlogs and capacity constraints.

Eligible women should maintain scheduled screening appointments. The AI operates invisibly; sample collection and result reporting procedures remain unchanged. What shifts is an imperceptible layer of algorithmic scrutiny—a trained system scanning your cells with consistency and precision, vigilant for cellular anomalies that demand clinical attention.